Early consolidation with high-dose therapy and autologous stem cell transplantation is a feasible and effective treatment option in HIV-associated non-Hodgkin lymphoma at high risk

[1]  M. Chiarini,et al.  B- and T-lymphocyte number and function in HIV+/HIV− lymphoma patients treated with high-dose chemotherapy and autologous bone marrow transplantation , 2016, Scientific Reports.

[2]  A. Krishnan,et al.  Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial. , 2016, Blood.

[3]  W. Wilson,et al.  Changes in the influence of lymphoma- and HIV-specific factors on outcomes in AIDS-related non-Hodgkin lymphoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  U. Tirelli,et al.  High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. , 2009, Blood.

[5]  N. Schmitz,et al.  Comparable survival between HIV+ and HIV- non-Hodgkin and Hodgkin lymphoma patients undergoing autologous peripheral blood stem cell transplantation. , 2009, Blood.

[6]  P. Biron,et al.  Autologous stem-cell transplantation in patients with HIV-related lymphoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Min Guan,et al.  Anti-HIV drugs for cancer therapeutics: back to the future? , 2009, The Lancet. Oncology.

[8]  S. Ibrahim,et al.  Regression of HIV-related diffuse large B-cell lymphoma in response to antiviral therapy alone. , 2008, Blood.

[9]  A. López-Guillermo,et al.  Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus‐associated diffuse large B‐cell lymphoma: results of a phase II trial , 2008, British journal of haematology.

[10]  A. Badley,et al.  HIV protease inhibitors impact on apoptosis. , 2008, Medicinal chemistry (Shariqah (United Arab Emirates)).

[11]  J. Park,et al.  Vascular endothelial growth factor gene polymorphisms and risk of colorectal cancer , 2007 .

[12]  T. Witte.  Stem Cell transplantation (SCT) for MDS. , 2007 .

[13]  C. Gisselbrecht,et al.  Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Nathwani,et al.  Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  E. Cesarman,et al.  Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. , 2005, Blood.

[16]  A. Nademanee,et al.  Autologous stem cell transplantation for HIV-associated lymphoma. , 2001, Blood.

[17]  G. Rossi,et al.  The International Prognostic Index can be used as a guide to treatment decisions regarding patients with human immunodeficiency virus—related systemic non‐Hodgkin lymphoma , 1999, Cancer.